Studies proposed for the first year of the Program Project Grant in clinical projects 3-5 will generate over 350 marrow, peripheral blood and cord blood samples (Tables 1,2,3). These samples will be distributed among the laboratories of the project leaders, core leaders and collaborators for assessment of phenotype, progenitor content, retroviral marking and evidence of contamination with malignant cells when relevant. The Sample Procurement Core (Core C) will support a centralized effort to procure and distribute samples generated by experiments proposed in Projects 3-5 to the appropriate research laboratories. Sample Procurement Core personnel will monitor patient entry into clinical trials and obtain required samples in a proactive fashion. Samples will be logged, and minimal processing (e.g., preparation of mononuclear cell fraction) performed under standard conditions. When appropriate, samples will be subjected to rate controlled freezing and stored in liquid nitrogen in a central facility under the supervision of Sample procurement Core Personnel. Either fresh or frozen samples will be delivered to the appropriate laboratories. These efforts will be supported by a core leader (Dr. Jeffrey Miller, M.D.) who is also an active investigator and research project leader (Project 2). The Sample procurement Core will serve as a resource for the entire program project which provides organization, integration, quality control and oversight coordinated by a single responsible core leader.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA065493-04
Application #
6269680
Study Section
Project Start
1998-09-30
Project End
1999-05-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Romee, Rizwan; Cooley, Sarah; Berrien-Elliott, Melissa M et al. (2018) First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131:2515-2527
Stefanski, Heather E; Jonart, Leslie; Goren, Emily et al. (2018) A novel approach to improve immune effector responses post transplant by restoration of CCL21 expression. PLoS One 13:e0193461
Owen, David L; Mahmud, Shawn A; Vang, Kieng B et al. (2018) Identification of Cellular Sources of IL-2 Needed for Regulatory T Cell Development and Homeostasis. J Immunol 200:3926-3933
Osborn, Mark J; Lees, Christopher J; McElroy, Amber N et al. (2018) CRISPR/Cas9-Based Cellular Engineering for Targeted Gene Overexpression. Int J Mol Sci 19:
Oh, Felix; Todhunter, Deborah; Taras, Elizabeth et al. (2018) Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin. Clin Pharmacol 10:113-121
Rashidi, Armin; Ebadi, Maryam; Said, Bassil et al. (2018) Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. Am J Hematol :
Bejanyan, Nelli; Brunstein, Claudio G; Cao, Qing et al. (2018) Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv 2:909-922
Bachanova, Veronika; Sarhan, Dhifaf; DeFor, Todd E et al. (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother 67:483-494
Xing, Yan; Smith, Michelle J; Goetz, Christine A et al. (2018) Thymic Epithelial Cell Support of Thymopoiesis Does Not Require Klotho. J Immunol 201:3320-3328
Prestipino, Alessandro; Emhardt, Alica J; Aumann, Konrad et al. (2018) Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med 10:

Showing the most recent 10 out of 395 publications